Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Elliott

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Leukemia Research|July 18, 2018
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblastsAbhishek A Mangaonkar, Naseema Gangat, Aref Al-Kali, et al.
American Journal of Hematology|August 12, 2022
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world settingAmritpal Singh, Aref Al-Kali, James M Foran, et al.
American Journal of Hematology|September 9, 2023
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcomeAnimesh Pardanani, Ayalew Tefferi, Aref Al-Kali, et al.
Mayo Clinic Proceedings|April 10, 2003
Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary reviewMichelle A Elliott, William L Nichols, Elizabeth A Plumhoff, et al.
European Journal of Haematology|October 26, 2011
Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapyMichelle A Elliott, Louis Letendre, Ayalew Tefferi, et al.
Leukemia & Lymphoma|August 31, 2018
Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic targetAbhishek A Mangaonkar, Mrinal M Patnaik, Gavin R Oliver, et al.
American Journal of Hematology|February 2, 2021
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapyKebede H Begna, Naseema Gangat, Aref Al-Kali, et al.
American Journal of Hematology|September 21, 2023
Mast cell cytomorphology and treatment outcome in mast cell leukemiaAyalew Tefferi, Animesh Pardanani, Aref Al-Kali, et al.
Leukemia & Lymphoma|May 10, 2017
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>Jason N Barreto, Kristen B McCullough, Candy S Peskey, et al.
Blood|July 27, 2006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani, Ross L Levine, Terra Lasho, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Leukemia Research|July 18, 2018
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblastsAbhishek A Mangaonkar, Naseema Gangat, Aref Al-Kali, et al.
American Journal of Hematology|August 12, 2022
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world settingAmritpal Singh, Aref Al-Kali, James M Foran, et al.
American Journal of Hematology|September 9, 2023
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcomeAnimesh Pardanani, Ayalew Tefferi, Aref Al-Kali, et al.
Mayo Clinic Proceedings|April 10, 2003
Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary reviewMichelle A Elliott, William L Nichols, Elizabeth A Plumhoff, et al.
European Journal of Haematology|October 26, 2011
Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapyMichelle A Elliott, Louis Letendre, Ayalew Tefferi, et al.
Leukemia & Lymphoma|August 31, 2018
Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic targetAbhishek A Mangaonkar, Mrinal M Patnaik, Gavin R Oliver, et al.
American Journal of Hematology|February 2, 2021
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapyKebede H Begna, Naseema Gangat, Aref Al-Kali, et al.
American Journal of Hematology|September 21, 2023
Mast cell cytomorphology and treatment outcome in mast cell leukemiaAyalew Tefferi, Animesh Pardanani, Aref Al-Kali, et al.
Leukemia & Lymphoma|May 10, 2017
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>Jason N Barreto, Kristen B McCullough, Candy S Peskey, et al.
Blood|July 27, 2006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani, Ross L Levine, Terra Lasho, et al.
Pageof 9